Translating induced pluripotent stem cells into drug discovery and regenerative medicine applications

Authors

• I Singec
• Y Chen
• P Ormanoglu
• S Titus
• C Austin
• A Simeonov

Abstract

Pluripotent stem cell research has made extraordinary progress over the last decade. Nuclear reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) by using defined factors has created entirely novel opportunities for drug discovery and personalized regenerative medicine. Patient- and disease-specific iPSCs can be expanded indefinitely and differentiated into relevant cell types of different organ systems. However, to move the iPSC technology more efficiently to clinical applications it is necessary to gain deeper insights into pluripotency, cellular differentiation, and functional maturation of precisely characterized cell types. Supported by the NIH Regenerative Medicine Program (RMP), the National Center for Regenerative Medicine (NCATS) has established the Stem Cell Translation Laboratory (SCTL). This presentation will highlight the multidisciplinary and collaborative efforts of the SCTL and provide examples on how to shed new light on human pluripotency and directed cell differentiation by using quantitative systems biology methods and high-throughput technologies.

Scientific Focus Area: Stem Cell Biology

This page was last updated on Friday, March 26, 2021